Table 4.
Serum Cancer Biomarkers at Baseline and 6 Months for Weight Loss Intervention Groups (n = 64) Versus Usual Care (n = 33) Among Participants With Fasting Baseline Serum (N = 97)
| Biomarker | Baseline, Mean (SE) | 6 Months, Mean (SE) | Change Over 6 Months, Mean (SE)* | Change, % |
|---|---|---|---|---|
| Insulin (μU/mL) | ||||
| Control | 19.04 (1.68) | 18.31 (1.60) | −0.54 (0.85) | −2.84 |
| Intervention | 17.25 (1.41) | 15.67 (1.36) | −1.68 (0.61) | −9.74 |
| P† | .44 | .24 | .28 | |
| Glucose (mg/dL) | ||||
| Control | 101.88 (2.48) | 102.39 (2.36) | 0.52 (1.44) | 0.51 |
| Intervention | 106.64 (2.62) | 104.61 (2.93) | −2.03 (1.03) | −1.90 |
| P† | .24 | .62 | .16 | |
| CRP (mg/L) | ||||
| Control | 4.77 (1.08) | 4.38 (0.95) | −0.06 (0.41) | −1.26 |
| Intervention | 3.50 (0.54) | 2.62 (0.33) | −1.05 (0.29) | −30.00 |
| P† | .24 | .04 | .05 | |
| Leptin (ng/mL) | ||||
| Control | 31.00 (3.04) | 28.49 (2.69) | −2.25 (1.72) | −7.26 |
| Intervention | 28.96 (2.05) | 23.99 (2.16) | −5.10 (1.23) | −17.61 |
| P† | .57 | .21 | .18 | |
| Adiponectin (μg/mg) | ||||
| Control | 13.75 (1.49) | 14.10 (2.00) | 0.28 (0.93) | 2.04 |
| Intervention | 15.02 (0.83) | 15.68 (0.82) | 0.70 (0.67) | 4.66 |
| P† | .42 | .39 | .71 | |
| IL-6 (pg/mL)‡ | ||||
| Control | 2.29 (0.33) | 2.23 (0.34) | −0.02 (0.18) | −0.87 |
| Intervention | 1.89 (0.15) | 2.16 (0.22) | 0.14 (0.13) | 7.41 |
| P† | 0.21 | 0.86 | 0.47 | |
| TNF-α (pg/mg) | ||||
| Control | 1.67 (0.08) | 1.61 (0.08) | −0.06 (0.08) | −3.59 |
| Intervention | 1.86 (0.08) | 1.80 (0.10) | −0.06 (0.05) | −3.17 |
| P† | 0.13 | 0.23 | 0.99 |
NOTE. Baseline serum biomarker values were imputed for 16 participants with missing values at 6 months.
Abbreviations: CRP, C-reactive protein; IL, interleukin; TNF, tumor necrosis factor.
*
Adjusted for baseline biomarker values for biomarker of interest.
†
P for F test comparing group means.
‡
n = 96; one participant excluded due to a baseline IL-6 level that was below the lower limit of detection.